Immune escape associated with functional defects in antigen-processing machinery in head and neck cancer

被引:173
作者
Ferris, Robert L.
Whiteside, Theresa L.
Ferrone, Soldano
机构
[1] Roswell Pk Canc Inst, Canc Cell Ctr, Dept Immunol, Buffalo, NY 14263 USA
[2] Univ Pittsburgh, Sch Med, Dept Immunol, Pittsburgh, PA USA
[3] Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA USA
[4] Univ Pittsburgh, Sch Med, Dept Otolaryngol, Pittsburgh, PA USA
[5] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA
关键词
D O I
10.1158/1078-0432.CCR-05-2750
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Recent revival of interest in the role of immune surveillance in the pathogenesis and control of malignant diseases has focused attention on escape mechanisms used by tumor cells to evade immune recognition. Defects in the host's tumor antigen-specific immune responses and abnormalities in tumor cell expression of HLA class I molecules and tumor antigen are known to contribute to tumor progression. However, the mechanism(s) responsible for the lack of tumor cell recognition by functional HLA class I antigen - restricted, tumor antigen-specific CTLs despite expression of the restricting HLA class I allele and targeted tumor antigen by tumor cells remain (s) unexplained. In squamous cell carcinomas of the head and neck (SCCHN), this type of tumor escape is a rule rather than the exception. Here, we discuss evidence pointing to functional defects in the antigen-processing machinery as one mechanism underlying resistance of SCCHN cells to recognition and lysis by HLA class I antigen - restricted, tumor antigen-specific CTL. In addition, based on the restoration by IFN-gamma of SCCHN cell sensitivity to recognition by these CTL, we suggest strategies that may improve the clinical course of the disease by enhancing susceptibility of malignant cells to immune recognition.
引用
收藏
页码:3890 / 3895
页数:6
相关论文
共 40 条
  • [1] TAP expression provides a general method for improving the recognition of malignant cells in vivo
    Alimonti, J
    Zhang, QJ
    Gabathuler, R
    Reid, G
    Chen, SS
    Jefferies, WA
    [J]. NATURE BIOTECHNOLOGY, 2000, 18 (05) : 515 - 520
  • [2] Development and characterization of human constitutive proteasome and immunoproteasome subunit-specific monoclonal antibodies
    Bandoh, N
    Ogino, T
    Cho, HS
    Hur, SY
    Shen, J
    Wang, X
    Kato, S
    Miyokawa, N
    Harabuchi, Y
    Ferrone, S
    [J]. TISSUE ANTIGENS, 2005, 66 (03): : 185 - 194
  • [3] Involvement of both intrinsic and extrinsic pathways in IFN-γ-induced apoptosis that are enhanced with cisplatin
    Barton, C
    Davies, D
    Balkwill, F
    Burke, F
    [J]. EUROPEAN JOURNAL OF CANCER, 2005, 41 (10) : 1474 - 1486
  • [4] Cancer immunotherapy: A treatment for the masses
    Blattman, JN
    Greenberg, PD
    [J]. SCIENCE, 2004, 305 (5681) : 200 - 205
  • [5] Campoli Michael, 2004, Breast Dis, V20, P105
  • [6] Classical and nonclassical HLA class I antigen and NK cell-activating ligand changes in malignant cells: Current challenges and future directions
    Chang, CC
    Campoli, M
    Ferrone, S
    [J]. ADVANCES IN CANCER RESEARCH, VOL 93, 2005, 93 : 189 - 234
  • [7] Chikamatsu K, 2003, CANCER RES, V63, P3675
  • [8] Tumor sensitivity to IFN-γ is required for successful antigen-specific immunotherapy of a transplantable mouse tumor model for HPV-transformed tumors
    Dominiecki, ME
    Beatty, GL
    Pan, ZK
    Neeson, P
    Paterson, Y
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2005, 54 (05) : 477 - 488
  • [9] Human leukocyte antigen (HLA) class I defects in head and neck cancer
    Ferris, RL
    Hunt, JL
    Ferrone, S
    [J]. IMMUNOLOGIC RESEARCH, 2005, 33 (02) : 113 - 133
  • [10] Molecular staging of cervical lymph nodes in squamous cell carcinoma of the head and neck
    Ferris, RL
    Xi, LQ
    Raja, S
    Hunt, JL
    Wang, J
    Gooding, WE
    Kelly, L
    Ching, J
    Luketich, JD
    Godfrey, TE
    [J]. CANCER RESEARCH, 2005, 65 (06) : 2147 - 2156